Status:
RECRUITING
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Early Breast Cancer
Ductal Breast Carcinoma In Situ
Eligibility:
FEMALE
20-85 years
Brief Summary
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Eligibility Criteria
Inclusion
- Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
- Patients undergoing breast-conserving surgery
- Age ≥ 20 years
- Karnofsky Performance Status (KPS) ≥70%
- Life expectancy ≥ 5 years
- Adequate renal and hepatic function
Exclusion
- Pregnant patients
- Patients requiring re-irradiation of the thoracic region
Key Trial Info
Start Date :
February 6 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2030
Estimated Enrollment :
315 Patients enrolled
Trial Details
Trial ID
NCT06984250
Start Date
February 6 2025
End Date
February 28 2030
Last Update
May 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, Taiwan, 100
2
National Taiwan University Hospital Yunlin Branch
Taipei, Taiwan, 632